Last reviewed · How we verify

NCT04402281: EDsuPAR

Use of suPAR Algorithm for the ED Decision Making

Completed Last updated 11 February 2022
What this trial tests

trial testing suPAR algoritm in Critical Illness in 1,800 participants. Completed in 1 June 2021.

Timeline
11 May 2020
Primary endpoint
1 June 2021
1 June 2021

Quick facts

Lead sponsorHelsinki University Central Hospital
StatusCompleted
Study typeOBSERVATIONAL
Enrollment1,800
Start date11 May 2020
Primary completion1 June 2021
Estimated completion1 June 2021
Sites1 location across Finland

Drugs / interventions tested

Conditions studied

Sponsor

Helsinki University Central Hospital

Who can join

Adults 18 to 104, any sex, with Critical Illness. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Will the use of a clinical decision algorithm in the ED improve discharge or admission decisions.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

  1. Utilization of Prognostic Biomarker Soluble Urokinase Plasminogen Activator Receptor in the Emergency Department: A Tool for Safe and More Efficient Decision-making.
    Holstein RM, Mäkinen MT, Castrén MK, Kaartinen JM. · · 2022 · cited 1× · PMID 35295966 · DOI 10.1177/11772719221081789

Verify or expand the search:

Other recruiting trials for Critical Illness

Currently open trials in the same condition.

Other Helsinki University Central Hospital trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04402281.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing